KEI Submission to Oregon Senate on R&D Cost Transparency Provisions in SB 793

Today, KEI submitted written testimony on SB 793 — a bill that is designed to allow the Oregon Department of Consumer and Business Services to investigate price increases for prescription drugs — in advance of a hearing before the Oregon Senate Committee on Health Care at 1:00 P.M. (PST) on March 9, 2017.

KEI asked the Committee to amend the bill to require more detailed disclosure of the costs associated with research and development, including per patient and per phase clinical trial costs, and to require that any data collected in pursuit of an investigation under the act be made available to the public.

Blog Entry:Zack Struver Add new comment Printer-friendly version Send by email Send by email